Tetra Bio-Pharma Inc. confirms its non-exclusive supply agreement for GMP-Grade THC with U.S.-based Rhodes Technologies Inc. The supply will be used for several drug development activities including Tetra’s cannabinoid-derived products PPP002, PPP003, and PPP004, as well as for discovery phase projects.
Tetra Bio-Pharma Inc. has announced that it is in process of filing a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that allows for patent protection.
Recent news regarding Aphria Inc. does not in any way affect Tetra’s business, operations, clinical and drug registration and source of supply. We are well funded to continue these activities in 2019 with plans to expand our clinical activities in the U.S.
Tetra Bio-Pharma Inc. announced that it held its first National Advisory Board meeting in Toronto, on November 30, 2018 as a platform to validate their drug development and commercial programs.
Tetra Natural Heath announces the delivery of twenty containers, more than 1.7 million cans of its product Hemp Energy Drink, the first hemp energy drink in Canada, to meet growing demand in Canada and to make Hemp Energy Drink available across all regions of the country.
Tetra Bio-Pharma Inc. has closed a private placement of units with its strategic partner Aphria Inc.
Tetra Bio-Pharma Inc. and Altus Formulation Inc. today announced the signing of a non-binding term sheet to create a joint-venture to formulate, develop and deliver cannabinoid derived therapeutics for a number of indications.
Tetra Bio-Pharma Inc. is pleased to update the market that Dr. Guy Chamberland , CEO and CSO of Tetra Bio-Pharma will be travelling to Washington, D.C. today for individual meetings with six high-ranking U.S. Senators.
Tetra Bio-Pharma Inc. is pleased to update the market on its strategic partnership with Sirius Air Solutions Inc. (previously known as AES) to secure a source of supply for a specialized cannabis smoke air purifying system and a mask designed for law and emergency responders.
Tetra Bio-Pharma Inc. and Quantum Pharma Inc. today announced the signing of a binding proposal for exclusive access to a Health Canada licensed facility (i.e., Drug Establishment License; DEL) that enables the company to produce cannabis and cannabinoid drug products for Tetra’s and Panag Pharma’s development activities including the ocular drug formulations.